Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + toripalimab with TACE and BAI versus donafenib + toripalimab for hepatocellular carcinoma with lung metastases
ChiCTR2100049493Phase 4Not yet recruiting
- Sponsor
- Department of Interventional Radiology, Chinese People's Liberation Army General Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of donafenib and toripalimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Department of Interventional Radiology, Chinese People's Liberation Army General Hospital. Primary endpoint: progression-free survival time. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
donafenibtoripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100049493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049493.